Shares in Bellerophon Therapeutics (NSDQ:BLPH) fell slightly today after the company missed earnings expectations on Wall Street with its fourth-quarter and full-year results.
The Warren, N.J.-based company posted a net loss of -$24.2 million, or -44¢ per share, for the 3 months ended Dec. 31. The company’s bottom-line losses grew -227% compared with the same period last year. Analysts were expecting earnings per share of -24¢.
Get the full story at our sister site, Drug Delivery Business News.
The post Bellerophon Therapeutics misses EPS estimates in Q4 appeared first on MassDevice.